surmount-1 tirzepatide weight loss percent nejm 2022 for Obesity Treatment and Diabetes Prevention Tirzepatide: In the SURMOUNT-1 trial,

Alternative treatments include other GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, or conventional diabetes therapies if Ozempic remains intolerable despite management strategies

While rodent studies prompted an FDA boxed warning about thyroid C-cell tumors, the relevance to humans remains unknown

For people researching tirzepatide cardiovascular benefits alongside weight loss, the evidence indicates broad cardiometabolic improvement that is likely both directly mediated by the drug and indirectly mediated through weight reduction

Understanding the relationship between tirzepatide dosing for weight loss in units and actual milligrams delivered is what separates people who get clinical-trial-level results from those who wonder why the medication is not working

Individual variation still exceeds the between-drug difference, and genetics may explain why